Headlands Technologies LLC Purchases 30,835 Shares of Syndax Pharmaceuticals, Inc. $SNDX

Headlands Technologies LLC increased its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 121.4% during the second quarter, HoldingsChannel reports. The institutional investor owned 56,227 shares of the company’s stock after acquiring an additional 30,835 shares during the period. Headlands Technologies LLC’s holdings in Syndax Pharmaceuticals were worth $1,229,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in SNDX. AQR Capital Management LLC lifted its stake in Syndax Pharmaceuticals by 478.8% in the first quarter. AQR Capital Management LLC now owns 377,444 shares of the company’s stock valued at $4,637,000 after acquiring an additional 312,231 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Syndax Pharmaceuticals by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,842 shares of the company’s stock worth $705,000 after purchasing an additional 3,094 shares during the last quarter. Caxton Associates LLP bought a new position in shares of Syndax Pharmaceuticals during the 1st quarter valued at $257,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Syndax Pharmaceuticals by 18.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 200,696 shares of the company’s stock valued at $2,466,000 after purchasing an additional 30,596 shares in the last quarter. Finally, Legal & General Group Plc lifted its stake in shares of Syndax Pharmaceuticals by 4.9% in the 2nd quarter. Legal & General Group Plc now owns 84,575 shares of the company’s stock valued at $792,000 after purchasing an additional 3,937 shares during the last quarter.

Insider Buying and Selling at Syndax Pharmaceuticals

In other Syndax Pharmaceuticals news, CEO Michael A. Metzger sold 32,375 shares of the company’s stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $24.24, for a total transaction of $784,770.00. Following the completion of the sale, the chief executive officer directly owned 484,843 shares in the company, valued at $11,752,594.32. This represents a 6.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CMO Nicholas A.J. Botwood sold 34,280 shares of the firm’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $18.00, for a total value of $617,040.00. Following the completion of the sale, the chief marketing officer directly owned 60,885 shares in the company, valued at approximately $1,095,930. This represents a 36.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 97,890 shares of company stock worth $1,968,413 in the last quarter. Insiders own 4.80% of the company’s stock.

Syndax Pharmaceuticals Trading Down 1.3%

NASDAQ:SNDX opened at $19.29 on Tuesday. The company’s 50 day moving average is $20.93 and its 200-day moving average is $21.26. The company has a quick ratio of 6.44, a current ratio of 6.77 and a debt-to-equity ratio of 38.95. Syndax Pharmaceuticals, Inc. has a 12 month low of $12.99 and a 12 month high of $25.59. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of -7.69 and a beta of 0.40.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.10). Syndax Pharmaceuticals had a negative return on equity of 372.94% and a negative net margin of 87.52%.The firm had revenue of $72.79 million for the quarter, compared to the consensus estimate of $79.36 million. During the same period in the prior year, the company posted ($0.83) earnings per share. Syndax Pharmaceuticals’s quarterly revenue was up 91.8% on a year-over-year basis. Equities analysts anticipate that Syndax Pharmaceuticals, Inc. will post -2.01 EPS for the current year.

Analysts Set New Price Targets

SNDX has been the subject of a number of recent research reports. Bank of America reiterated a “buy” rating on shares of Syndax Pharmaceuticals in a report on Wednesday, August 5th. HC Wainwright cut their target price on Syndax Pharmaceuticals from $40.00 to $38.00 and set a “buy” rating on the stock in a report on Wednesday, August 5th. UBS Group reduced their price target on Syndax Pharmaceuticals from $37.00 to $33.00 and set a “buy” rating for the company in a research report on Friday, August 21st. JPMorgan Chase & Co. decreased their price target on Syndax Pharmaceuticals from $44.00 to $40.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. Finally, Weiss Ratings raised Syndax Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 21st. Twelve analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.55.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.